Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $39.88

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target […]

Leave a Reply

Your email address will not be published.

Previous post One in ten startup owners blame the Government for business failure, survey finds
Next post Veeva Systems Inc. (NYSE:VEEV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages